Purgo Scientific, Inc., a biotechnology company focused on advanced localized therapeutic delivery technologies, today highlighted continued commercial progress within its veterinary subsidiary, Vetlen, following Vetlen’s previously announced distribution partnership with Patterson Equine. 

The partnership with Patterson Equine expands access to the Vetlen Pouch through one of the leading equine veterinary distribution networks in the United States, supporting broader availability of the technology to veterinary professionals. 

The Vetlen Pouch is designed to support localized delivery of therapeutics directly at the surgical site and is currently being utilized in equine veterinary applications. 

“Expanding commercial access through established veterinary distribution channels represents an important milestone for our organization,” said, Mike Benjamin, Interim CEO of Purgo Scientific. “This progress reflects the continued evolution of our platform from development into commercialization and helps position the company for broader market adoption.” 

Purgo Scientific continues to advance both its veterinary and human health programs as the company expands manufacturing, commercialization, and regulatory activities across its platform technologies.

For additional details regarding the Patterson Equine distribution agreement, please see Vetlen’s original announcement here. 

About Purgo Scientific 
Purgo Scientific is a biotechnology company developing localized drug delivery technologies designed to improve therapeutic delivery directly at the site of care. The company is advancing applications across both veterinary and human health markets through its proprietary platform technologies. 

About Vetlen 
Vetlen is a veterinary health company focused on localized therapeutic delivery solutions designed to support surgical and procedural applications in animal health.